【摘要】 目的：探究乳腺癌患者术前采用新辅助化疗的效果。方法：选取2018年1月-2019年8月福建医科大学附属龙岩第一医院60例乳腺癌患者为研究对象。根据简单随机化法将其分为试验组和对照组，各30例。试验组给予术前新辅助化疗与保乳术治疗，对照组给予保乳术治疗。比较两组治疗前后肿瘤标志物水平，不良反应及预后情况。结果：试验组治疗后癌胚抗原（CEA）、糖类抗原125(CA125)、糖类抗原153(CA153)水平均低于对照组（P<0.05）。两组不良反应、远处转移、术后复发发生率比较差异均无统计学意义（P>0.05），试验组生存率高于对照组（P<0.05）。结论：乳腺癌患者术前接受新辅助化疗，可更好改善患者的肿瘤标志物水平和预后，意义重大。更多还原

【Abstract】 Objective: To explore the effect of preoperative neoadjuvant chemotherapy on patients with breast cancer. Method: A total of 60 patients with breast cancer in Longyan First Hospital Affiliated to Fujian Medical University from January 2018 to August 2019were selected as the study subjects. According to the simple randomization method, they were divided into experimental group and control group, 30 cases in each group. The experimental group was treated with preoperative neoadjuvant chemotherapy and breast conserving surgery, and the control group was treated with breast conserving surgery. The levels of tumor markers before and after treatment,adverse reactions and prognosis were compared between the two groups. Result: After treatment, the levels of carcinoembryonic antigen(CEA), carbohydrate antigen 125(CA125) and carbohydrate antigen 153(CA153) in the experimental group were lower than those in the control group(P<0.05). There were no significant differences in the incidences of adverse reactions, distant metastasis and postoperative recurrence between the two groups(P>0.05), and the survival rate of the experimental group was higher than that of the control group(P<0.05). Conclusion: Preoperative neoadjuvant chemotherapy in patients with breast cancer can better improve the level of tumor markers and prognosis of patients, which is of great significance.更多还原